Zimislecel

Zimislecel : Recently, a landmark clinical advancement demonstrated that a therapy using lab-grown islet cells, called zimislecel, has the potential to restore insulin production in individuals with severe Type 1 diabetes.

• About Zimislecel : A novel therapy that involves infusing lab-grown islet cells, derived from pluripotent stem cells, into the liver via the hepatic portal vein.

o These islet cells replace the insulin-producing beta cells destroyed by the immune system in Type 1 diabetes.

o Once implanted, the cells begin producing insulin naturally from within the body.

o Clinical Trial Overview: Phase 1/2 trial included 12 patients with severe, long-standing Type 1 diabetes. Participants had poor glucose control and a history of life-threatening hypoglycaemic episodes.

o Key Findings: Insulin production restored: All 12 patients began producing C-peptide, a marker of insulin secretion—within 90 days.

- Improved blood sugar control: HbA1c levels dropped below 7% in all participants within four months.

- Reduced insulin dependence: 10 out of 12 participants were able to completely stop insulin injections.

- Better glucose range stability: Time in target blood glucose range increased from 50% to over 93%.

• About Type 1 Diabetes : Caused by the immune system attacking the pancreas’s insulin-producing islet cells, stopping natural insulin production.

o Patients must rely on external insulin injections and continuous glucose monitoring to manage their condition. Nearly 75% of individuals with Type 1 diabetes are unable to consistently achieve target glucose levels.

o Poor glucose control increases the risk of long-term complications, including nerve damage, kidney disease, and cardiovascular issues.